Shock Clinical Trial - Dobutamine in the Treatment of Haemodynamic

Status Terminated

Clinical Trial Summary

Haemodynamic insufficiency after birth is seen commonly in babies born prematurely and is associated with adverse outcomes. In current clinical practice, a combination of blood pressure and clinical signs is used to guide therapy. However, blood pressure is a poor surrogate of systemic and organ (brain) blood flow distribution during transitional circulation. This state is characterised by increased peripheral vascular resistance and increased afterload causing myocardial depression and impaired blood flow distribution in spite of 'normal' blood pressure. Echocardiography-Doppler (Echo-D) measurement of superior vena cava (SVC) flow has been proposed as a more clinically relevant marker of circulatory impairment shortly after birth than systemic hypotension. When there is low SVC flow, several small-scale clinical trials have suggested dobutamine as the optimal therapeutic option. However the associations between SVC flow and short- and long- term outcomes are not strong enough to allow SVC flow alone to be the basis for the inclusion of patients into a confirmatory trial to demonstrate the efficacy and safety of dobutamine.

NeoCirc-001 - The primary objective is to answer some important questions required for the design of a subsequent placebo-controlled trial (NeoCirc-003), which will evaluate the effectiveness of a new neonatal formulation of dobutamine to treat haemodynamic insufficiency in the first 72 hours after birth in babies born at less than 33 weeks' gestation. Observational data will be collected from this population with a view to determining the degree to which diagnostic measures influence treatment decisions. The primary outcome is death or worst cranial ultrasound (CUS) appearance at or before 36 weeks' gestation.

NeoCirc-001A - The primary objective is to estimate the elimination half-life, and consequently the time to steady-state of dobutamine in extremely premature neonates.

NeoCirc-001B - The primary objective is to construct a population pharmacokinetic pharmacodynamic model that will be validated using samples collected during the confirmatory trial (NeoCirc-003).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Shock

Clinical Trial Details

NCT number	NCT03311178
Study type	Interventional
Source	Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	May 30, 2014
Completion date	October 10, 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05898126` - Renin-guided Hemodynamic Management in Patients With Shock	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT05066256` - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock	N/A
Not yet recruiting	`NCT06285513` - Cardiovascular Metabolic Remodeling in Shock
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Terminated	`NCT02755155` - Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients	Phase 4
Not yet recruiting	`NCT01941472` - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness	N/A
Completed	`NCT01680783` - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure	N/A
Terminated	`NCT01696175` - PICU Admission Lactate and Central Venous Oxymetry Study	N/A
Recruiting	`NCT01157299` - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO	N/A
Recruiting	`NCT01174966` - Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients	N/A
Completed	`NCT00743522` - Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
Completed	`NCT03296891` - Point of Care Ultrasonography In The Management of Shock: A Pilot Study	N/A
Recruiting	`NCT05922982` - Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery	N/A
Withdrawn	`NCT04705701` - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care	N/A
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed	`NCT05330676` - Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Active, not recruiting	`NCT04079829` - Postoperative Respiratory Abnormalities
Completed	`NCT04089098` - VOLume and Vasopressor Therapy in Patients With Hemodynamic instAbility
Completed	`NCT03190408` - Variation in Fluids Administered in Shock

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period — NeoCirc-001

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms